Acute Myelogenous Leukemia (AML) News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

French Biotech Misfires in Phase IIb Trial for Acute Myeloid Leukemia - Labiotech.eu (blog)



Labiotech.eu (blog)
 
French Biotech Misfires in Phase IIb Trial for Acute Myeloid Leukemia 
Labiotech.eu (blog)
Erytech, based in Lyon, France, has developed an interesting approach to delivering drugs for the treatment of cancer and orphan diseases. The company's eryaspase technology, Graspa, encapsulates L-asparaginase, in red blood cells. Graspa was used in ...
ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML GlobeNewswire (press release)
Erytech rocked by phase 2b failure in AML FierceBiotech
ERYTECH's lead product candidate flunks mid-stage AML study; shares off 28% premarket Seeking Alpha
Rare Disease Report 
all 8 news articles » 


Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of ... - Business Wire (press release)



Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of ... 
Business Wire (press release)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced initial clinical data from ...
Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a ... Digital Journal

all 2 news articles » 


Unforeseen new drug target discovered for acute myeloid leukemia - Science Daily



Science Daily
 
Unforeseen new drug target discovered for acute myeloid leukemia 
Science Daily
Reported in the journal Nature today (27 November), the study goes on to reveal why METTL3 is required for AML cell survival, by deciphering the new mechanism it uses to regulate several other leukemia genes. Acute myeloid leukemia (AML) is an ...

and more » 


Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613 in Treating Acute Myeloid Leukemia at the ... - GlobeNewswire (press release)



Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613 in Treating Acute Myeloid Leukemia at the ... 
GlobeNewswire (press release)
Newark, NJ, Dec. 07, 2017 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by targeting mitochondrial metabolism ...
Acute Myeloid Leukemia (AML) Therapeutics Market Is Expected To Reach US$ 1025.9 Mn By 2025 ? Acute Market ... Digital Journal

all 2 news articles » 


ImmunoGen Presents New Clinical and Preclinical Data at ASH Annual Meeting - Business Wire (press release)



ImmunoGen Presents New Clinical and Preclinical Data at ASH Annual Meeting 
Business Wire (press release)
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new data from the Company's ongoing Phase 1 study of IMGN779, a next ...

 


The Leukemia & Lymphoma Society Achieves New Milestones in Offensive Against Acute Myeloid Leukemia, Deadly ... - PR Newswire (press release)



The Leukemia & Lymphoma Society Achieves New Milestones in Offensive Against Acute Myeloid Leukemia, Deadly ... 
PR Newswire (press release)
RYE BROOK, N.Y., Dec. 6, 2017 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma SocietyŽ (LLS) continues its assault against acute myeloid leukemia (AML), a deadly blood cancer that kills more than 10,000 Americans a year. LLS today announced its ...

and more » 


High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML - Cancer Therapy Advisor



Cancer Therapy Advisor
 
High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML 
Cancer Therapy Advisor
Cytarabine induction therapy with dose escalation is well-tolerated and prolongs disease-free survival (DFS) among patients with acute myeloid leukemia (AML) compared with conventional doses. The findings were presented at the 2017 American Society of ...

and more » 


Trovagene Announces Activation of First Clinical Trial Site in Phase ... - PR Newswire (press release)



Trovagene Announces Activation of First Clinical Trial Site in Phase ... 
PR Newswire (press release)
SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the activation of its clinical trial site for its Phase 1b/2 multicenter trial of PCM-075 in patients with AML, with ...

and more » 


AML Field Advances With New Agents, But More Work Remains - OncLive



OncLive
 
AML Field Advances With New Agents, But More Work Remains 
OncLive
With all those drugs becoming FDA approved, now there are all various possible combinations being explored?in different settings, with transplant, and with maintenance therapy. All of these studies are in the process. There are other drugs that are ...
Acute Myeloid Leukemia (AML) Therapeutics Market to Discern ... MilTech

all 4 news articles » 


Long-term Effects of Midostaurin Maintenance Are Unknown in FLT3 ... - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Long-term Effects of Midostaurin Maintenance Are Unknown in FLT3 ... 
Cancer Therapy Advisor
At the end of maintenance, 57% and 64% of patients remained in the midostaurin arm or the placebo arm, respectively.